聚焦2026 IDSA指南:抗菌药物耐药性革兰氏阴性菌感染的治疗(英)。with ESBL-E uUTIs (56% [41/73] vs 47% [34/72]) [48]. Mild diarrhea is the most common adverse event associated with sulopenem. Notably, probenecid inhibits tubular secretion and may increase plasma concentrations of other drugs (eg methotrexate, piperacillin, and sulfonamides) [49].
聚焦2026 IDSA指南:抗菌药物耐药性革兰氏阴性菌感染的治疗(英)。with ESBL-E uUTIs (56% [41/73] vs 47% [34/72]) [48]. Mild diarrhea is the most common adverse event associated with sulopenem. Notably, probenecid inhibits tubular secretion and may increase plasma concentrations of other drugs (eg methotrexate, piperacillin, and sulfonamides) [49].
聚焦2026 IDSA指南:抗菌药物耐药性革兰氏阴性菌感染的治疗(英)。with ESBL-E uUTIs (56% [41/73] vs 47% [34/72]) [48]. Mild diarrhea is the most common adverse event associated with sulopenem. Notably, probenecid inhibits tubular secretion and may increase plasma concentrations of other drugs (eg methotrexate, piperacillin, and sulfonamides) [49].
覆盖 2026 年,全文共 52 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了药物、IDSA指南等议题。